Organization (Industry)
THERMO FISHER SCIENTIFIC INC.
ClinicalTrials.gov lists THERMO FISHER SCIENTIFIC INC. as lead sponsor of 17 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through October, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to October, under the 5 a year the method needs.
Logo Thermo Fisher Scientific, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers THERMO FISHER SCIENTIFIC INC. and 16 companies with a profile grouped under it (a further 59 registry-linked records in the group have no profile): 17 lead-sponsored trials (3 its own, 14 in the grouped companies) and 37 legal-entity registrations (8 its own, 29 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (16)
Shown in this order: most lead trials first.
| Company | Country | Lead trials | Legal entities |
|---|---|---|---|
| BRAHMS | BE | 8 | 1 |
| PPD Development, L.P. | 5 | 1 | |
| Life Technologies | 1 | 9 | |
| Center for Clinical and Basic Research A/S | DK | 0 | 2 |
| Fisher Bioservices (United States) | US | 0 | 1 |
Showing 5 of 16 member companies.
Counts companies with a profile grouped under this one. A further 59 registry-linked records in this group have no company profile and are not listed.
Disease areas (69)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Inflammation | 6 |
| Diabetes Insipidus | 5 |
| Sepsis | 5 |
| Emergencies | 3 |
| Food Hypersensitivity | 3 |
Showing 5 of 69 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 4 |
| 2022 | 2 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 2 |
| 2014 | 2 |
| 2013 | 2 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: none of the 3 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 3 hit target (n=3) | 0 of 3 on time (n=3) |
Journals published in (63)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of allergy and clinical immunology | 7 |
| Critical care (London, England) | 5 |
| The New England journal of medicine | 4 |
| BMJ open | 3 |
| Journal of the American College of Cardiology | 3 |
Showing 5 of 63 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 3,237 | 546 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts; non-USD filers converted to USD at the annual average rate.
| Fiscal year | Revenue | Net income | R&D |
|---|---|---|---|
| 2025 | $44.6B | $6.70B | $1.40B |
| 2024 | $42.9B | $6.34B | $1.39B |
| 2023 | $42.9B | $6.00B | $1.34B |
| 2022 | $44.9B | not reported | $1.47B |
| 2021 | $39.2B | not reported | $1.41B |
| 2020 | $32.2B | not reported | $1.18B |
| 2019 | $25.5B | not reported | $1.00B |
| 2018 | $24.4B | not reported | $967M |
| 2017 | $20.9B | not reported | $887M |
| 2016 | $18.3B | not reported | $754M |
Showing 10 of 11 fiscal years.
Financing and grant events (70)
Shown in this order: most recent first; amounts in US dollars.
| Date | Round type | Amount | Source |
|---|---|---|---|
| 2026-02-12 | Debt financing | $3.76B | SEC extracted |
| 2026-02-10 | Debt financing | $3.80B Registered offering ceiling | EDGAR offerings |
| 2026-02-09 | Other financing | not disclosed | EDGAR offerings |
| 2025-12-01 | Debt financing | not disclosed | SEC extracted |
| 2025-11-25 | Debt financing | $2.42B Registered offering ceiling | EDGAR offerings |
Showing 5 of 70 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 54 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 4 | 2020-10-16 |
Manufacturing and distribution sites (23)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Patheon Inc. | 2100 Syntex Court, Mississauga, CA | FDA, Health Canada | Patheon (Canada) |
| Patheon UK Limited | Kingfisher Drive, Swindon, GB | FDA, Health Canada | Patheon UK Limited |
| Patheon Pharmaceuticals Inc. | 2110 E Galbraith Rd., Cincinnati, US | FDA, Health Canada | Patheon Pharmaceuticals Inc. |
| Patheon Inc. | 111 Consumers Drive, Whitby, CA | FDA, Health Canada | Patheon (Canada) |
| Life Technologies Corporation | 7335 Executive Way, FREDERICK, US | FDA | Life Technologies Corporation |
Showing 5 of 23 sites.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (27)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Thermo Fisher Scientific (United States) | Parent of | 14 |
| Thermo Fisher Scientific (United States) | Ultimate parent of | 14 |
| Bristol Myers Squibb Co | Co sponsors trial with | 1 |
| Astrazeneca Plc | Co sponsors trial with | 1 |
| Labcorp Holdings Inc. | Co sponsors trial with | 1 |
Showing 5 of 27 relationships.
Latest dated events (3,508)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-17 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-08-13 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-07-23 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-06-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-03 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 3,508 events.
Biomarker capability evidence (28)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACTG1 | Trial collaborator | Named in trial inclusion criteria |
| NPPB | Trial collaborator | Named in trial inclusion criteria |
| ACE | Trial collaborator | Named in trial exclusion criteria |
| ACE | Trial collaborator | Named in trial exclusion criteria |
| ACE | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 28 evidence rows.
On Scientist.com
THERMO FISHER SCIENTIFIC INC. is listed as a research supplier in the Scientist.com network.
Service areas
Olink Bioscience provides protein interaction detection, antibody probes, detection kits, assay development, and reagent manufacturing.
- Website
- www.olink.com
Not on this page
Checked, with nothing recorded for this organization: active development programs, approved assets, fda warning letters, fda untitled letters, fda recalls, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Olink Proteomics AB on Scientist.com
For prices, more details, or to contact Olink Proteomics AB, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.